Assessment of Adipocyte Transduction Using Different AAV Capsid Variants

被引:0
|
作者
Boychenko, Stanislav [1 ]
Abdullina, Alina [1 ]
Laktyushkin, Viktor S. [2 ]
Brovin, Andrew [1 ]
Egorov, Alexander D. [1 ]
机构
[1] Sirius Univ Sci & Technol, Sci Ctr Translat Med, Gene Therapy Dept, Sirius 354340, Russia
[2] Sirius Univ Sci & Technol, Resource Ctr Cell Technol, Lab Complex, Sirius 354340, Russia
基金
俄罗斯科学基金会;
关键词
adeno-associated virus; viral tropism; adipocytes; adipose tissue; anti-obesity agents; gene therapy; ADIPOSE-TISSUE; VECTORS; TARGET;
D O I
10.3390/ph17091227
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background/Objectives: Adeno-associated viruses (AAVs) are widely used as viral vectors for gene delivery in mammalian cells. We focused on the efficacy of the transduction of AAV2/5, 2/6, 2/8 and 2/9 expressing GFP in preadipocyte cells by live imaging microscopy using IncuCyte S3 and flow cytometry. Methods: Three transduction modes in 3T3-L1 preadipocyte cells assessed: AAV transduction in 3T3-L1 preadipocyte cells, transduction with further differentiation into mature adipocyte-like cells and the transduction of differentiated 3T3-L1 adipocytes. For the in vivo study, we injected AAV2/6, AAV2/8 and AAV2/9 in adipose tissue of C57BL6 mice, and the transduction capacity of AAV2/6, along with AAV2/8 and AAV2/9 was evaluated. Results: AAV2/6 demonstrated the highest transduction efficiency in 3T3-L1 preadipocytes, as it was 1.5-2-fold more effective than AAV2/5, and AAV2/8 in the range of viral concentrations from 2 x 104 to 1.6 x 105 VG/cell. AAV2/5 and AAV2/8 showed transduction efficiencies similar to each other. The expression of GFP under the CMV promoter remained stable for up to 20 days. The induction of 3T3-L1 differentiation in three days after AAV transduction did not alter the GFP expression level, and AAV2/6 showed the best transduction efficiency. AAV2/6 demonstrated the ability to transduce mature adipocytes. These results were confirmed by in vivo studies on C57BL6 mice. AAV2/6 had the highest transducing activity on both inguinal and interscapular adipose tissue. Conclusions: Thus, AAV2/6 has demonstrated higher transduction efficacy compared to AAV2/5, AAV2/8 and AAV2/9 both in 3T3-L1 adipocytes and adipose tissue in vivo, which proves its usability along with AAV2/8 and AAV2/9 for gene delivery to adipocytes.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] AAV Capsid Assembly Using Escherichia Coli
    Dinh To Le
    MOLECULAR THERAPY, 2020, 28 (04) : 79 - 79
  • [32] Localization of Structural Determinants in AAV Capsid for Efficient Liver Transduction by Domain Swapping between AAV-2 and AAV-8
    Shen, Xuan
    Xu, Hui
    Storm, Theresa
    Kay, Mark A.
    MOLECULAR THERAPY, 2006, 13 : S288 - S288
  • [33] In Vitro Characterization of Novel AAV-Spark100 and AAV-Spark200 Capsid Variants
    Yazicioglu, Mustafa N.
    Armour, Sean M.
    Keiser, Nicholas W.
    Mingozzi, Federico
    Anguela, Xavier M.
    MOLECULAR THERAPY, 2018, 26 (05) : 47 - 48
  • [34] Adeno-associated Virus (AAV) Capsid Chimeras with Enhanced Infectivity Reveal a Core Element in the AAV Genome Critical for both Cell Transduction and Capsid Assembly
    Viney, Lydia
    Burckstummer, Tilmann
    Eddington, Courtnee
    Mietzsch, Mario
    Choudhry, Modassir
    Henley, Tom
    Agbandje-McKenna, Mavis
    JOURNAL OF VIROLOGY, 2021, 95 (07)
  • [35] Tri-GalNAc Conjugation to AAV Capsid Enhances Transduction of Human Hepatocytes In Vitro
    Chang, Hao
    Jiang, Jun
    Ren, Lingzhi
    Liang, Jialing
    Gao, Guangping
    Wang, Dan
    MOLECULAR THERAPY, 2022, 30 (04) : 461 - 461
  • [36] Elucidating the Mechanism of Species Specificity of Recombinant AAV Capsid Vector-Mediated Transduction
    Tsuji, Shinnosuke
    Kay, Mark A.
    MOLECULAR THERAPY, 2019, 27 (04) : 220 - 221
  • [37] AAV-S: A versatile capsid variant for transduction of mouse and primate inner ear
    Ivanchenko, Maryna, V
    Hanlon, Killian S.
    Hathaway, Daniel M.
    Klein, Alex J.
    Peters, Cole W.
    Li, Yaqiao
    Tamvakologos, Panos, I
    Nammour, Josette
    Maguire, Casey A.
    Corey, David P.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 21 : 382 - 398
  • [38] Directed Evolution of Enhanced AAV Capsid Variants Following Intravitreal Injection in Macaque
    Boye, Sanford L.
    Choudhury, Shreyasi
    Marsic, Damien
    Strang, Christianne E.
    Alexander, John J.
    Witherspoon, C. Douglas
    Zolotukhin, Sergei
    Gamlin, Paul D.
    Boye, Shannon Elizabeth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [39] Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants
    Weinmann, Jonas
    Weis, Sabrina
    Sippel, Josefine
    Tulalamba, Warut
    Remes, Anca
    El Andari, Jihad
    Herrmann, Anne-Kathrin
    Pham, Quang H.
    Borowski, Christopher
    Hille, Susanne
    Schoenberger, Tanja
    Frey, Norbert
    Lenter, Martin
    VandenDriessche, Thierry
    Mueller, Oliver J.
    Chuah, Marinee K.
    Lamla, Thorsten
    Grimm, Dirk
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [40] Identification and validation of novel engineered AAV capsid variants targeting human glia
    Giacomoni, Jessica
    Akerblom, Malin
    Habekost, Mette
    Fiorenzano, Alessandro
    Kajtez, Janko
    Davidsson, Marcus
    Parmar, Malin
    Bjorklund, Tomas
    FRONTIERS IN NEUROSCIENCE, 2024, 18